Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Autism
Interventions: Playground Intervention, STAT Intervention; Behavioral
Lead sponsor: Health Resources and Services Administration (HRSA); Federal
Eligibility: 4 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, New York • Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: CANA/MET XR FDC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Lymphoma, Non-Hodgkin
Interventions: SB-485232, Rituximab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • Indianapolis, Indiana

Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 634
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more

Conditions: Autism Spectrum Disorder, Repetitive Compulsive Behavior
Interventions: FITBI, Parental Education; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 3 Years to 9 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy
Interventions: LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions: Beta blockers; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 98
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more

Conditions: Tumor, Cancer
Interventions: AZD6244; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, Dexamethasone; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: PC14586; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hepatocellular Carcinoma
Interventions: TheraBionic Device, Placebo Device, Quality of Life Assessment; Device
Lead sponsor: THERABIONIC INC.; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Tampa, Florida • Chicago, Illinois • Winston-Salem, North Carolina + 4 more

Conditions: GastroEsophageal Cancer
Interventions: Immune checkpoint inhibitor (ICI) or chemotherapy alone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers
Interventions: TAK-788, Itraconazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Adenocarcinoma of Lung, Lung Cancer
Interventions: Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed, Placebo; Drug · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more

Conditions: Diet, Food and Nutrition
Interventions: UPF Test Diet A: Starchy, refined grains, UPF Test Diet B: Meat, fish, and bread products, UPF Diet C: Dairy products, including cheese and cream; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 20 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease, Diabetic Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Phoenix, Arizona • Tempe, Arizona • Azusa, California + 23 more

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Oral GW679769, IV Cyclophosphamide 500-700mg/m2; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Newark, Delaware • Albuquerque, New Mexico • The Bronx, New York

Conditions: Breast Cancer
Interventions: Ribociclib, T-DM1, Trastuzumab, Fulvestrant; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cardiotoxicity
Interventions: antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers; Other · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions: Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Somerset, New Jersey

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Part A: Placebo, Nintedanib, GSK3915393; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Cypress, California • Las Vegas, Nevada

Conditions: Suicide Prevention
Interventions: " Safer Still " Interactive Intervention, Enhanced Usual Care (EUC):; Behavioral · Other
Lead sponsor: Jeff Bridge; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Immune Thrombocytopenia
Interventions: Eltrombopag, Romiplostim, healthy controls; Drug · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Family-Implemented Treatment on the Behavioral Inflexibility of Children With Autism

A Study of LY3154885 in Healthy Participants

Impact of Beta-blockers on Physical Function in HFpEF

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Metabolomics-Driven Insights Into Ultra-Processed Foods

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Cyclophosphamide Drug Interaction Study In Cancer Patients

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

A Study of Blood Pressure Control During Cancer Treatment

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

Safer Still (Exploratory Project 3)

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)